Moonwalk's $70M Leap: A New Signal in the Battle Against Obesity

SOUTH SAN FRANCISCO & SAN DIEGO – September 08, 2026 – Moonwalk Biosciences, a biotech firm aiming to chart a new course in metabolic disease, has secured a significant $70 million in an oversubscribed Series B financing round. The funding, co-led by Alpha Wave and YK Bioventures, will fuel the development of its novel obesity therapies, which promise a fundamentally different approach to a global health crisis. The capital infusion is a powerful growth signal, not just for Moonwalk, but for the entire obesity treatment landscape, especially with pharmaceutical giant Eli Lilly and Company joining the syndicate of investors.

The proceeds are earmarked to advance Moonwalk's lead candidate, MW101, into its first human clinical trials by late 2027 and to expand its pipeline of medicines that use RNA interference (RNAi) to target adipose, or fat, tissue directly. This fresh capital validates the company’s strategy and provides the runway needed to test a new hypothesis in a market currently dominated by appetite-suppressing drugs.

A New Signal in the Obesity Market

The participation of Eli Lilly, a dominant force in the current obesity market with its blockbuster GLP-1 drugs Zepbound and Mounjaro, is perhaps the most telling signal from this funding round. While seemingly a small investment for a company of Lilly's scale, it represents a strategic bet on a next-generation technology that could complement or even compete with its existing portfolio. It suggests that even the market leaders are actively looking beyond the current incretin-based mechanisms, anticipating a future where treatment is more nuanced and personalized.

This move comes as the obesity drug market is projected to skyrocket, with some analysts forecasting it could reach $150 billion by 2035. This explosive growth has attracted a wave of innovation, with over 150 programs in development. Moonwalk is positioning itself as a key player in the next wave, which focuses on mechanisms beyond appetite control.

“Obesity is one of the most significant global health challenges, and Moonwalk is pursuing a fundamentally different approach to treating it,” said Rick Gerson, co-founder, Chairman and CEO of Alpha Wave Global, in a statement. His firm's co-lead on the investment underscores confidence in this differentiated strategy. By moving away from the brain's satiety centers and targeting the biology of fat cells themselves, Moonwalk aims to address some of the current therapies' limitations, such as muscle loss and gastrointestinal side effects.

The Science of Selective Silencing

At the heart of Moonwalk's approach is RNA interference, a Nobel Prize-winning technology that allows for the precise "silencing" of specific genes. The company is developing therapies that deliver small interfering RNA (siRNA) molecules directly to fat cells, turning down the activity of genes that contribute to unhealthy fat storage and metabolic dysfunction.

This adipose-targeting technology, licensed exclusively from Suzhou Siran Biotechnology, is the key differentiator. Preclinical studies have shown promising results: robust reductions in body weight and fat mass while preserving lean muscle. This is a critical point of distinction, as maintaining muscle is vital for long-term metabolic health. Furthermore, the approach does not reduce food intake, potentially avoiding the nausea and other digestive issues that can be challenging for patients on current GLP-1 treatments.

“What stood out to us about Moonwalk is the depth of the science behind the platform and the strength of the preclinical evidence generated to date,” noted Chris Dimitropoulos, Managing Director, Life Sciences Investments of Alpha Wave Global. “By combining adipose-selective RNAi delivery with human genetics, epigenomics and multi-omics discovery, the Moonwalk team has devised a highly precise way to modulate adipose biology.”

The company’s proprietary AI-enabled discovery platform allows it to sift through vast amounts of genetic and epigenetic data to identify novel targets. According to CEO and co-founder Dr. Alex Aravanis, the undisclosed gene target for MW101 was identified through this platform and is associated with natural leanness in humans without negative health consequences. The potential for infrequent dosing—perhaps only quarterly or twice a year, as suggested by primate studies—adds another layer of potential patient benefit, dramatically improving convenience over daily or weekly injections.

The Path to the Clinic and Beyond

With funding secured, Moonwalk's immediate focus is on completing the necessary IND-enabling studies to get MW101 into its first-in-human trial by late 2027. This marks the beginning of a long and rigorously regulated journey. RNAi therapies, while no longer new to medicine, still face high regulatory scrutiny, particularly regarding the specificity of their targeting and the safety of their delivery vehicles.

However, Moonwalk may have a tailwind. The chemistry it licensed from Suzhou Siran Biotechnology is part of a platform that has already been validated, not only by its own preclinical data but also by the market. Suzhou Siran recently entered a major licensing deal with GSK for a similar adipose-targeted siRNA, a move that lends significant credibility to the underlying technology's potential and regulatory viability. This precedent could help smooth the path for Moonwalk as it engages with regulators like the FDA.

Leadership and Strategic Alliances

Navigating this complex journey requires experienced leadership, and Moonwalk appears well-equipped. CEO Alex Aravanis is a veteran of the genomics revolution, having previously served as Chief Technology Officer at Illumina and co-founded the early cancer detection firm GRAIL. His expertise in leveraging large-scale biological data is central to the company's discovery engine.

The team has been further strengthened by the recent appointment of Dr. Stephen Djedjos as Senior Vice President of Clinical Development. With over 20 years of experience, including work on the development of Amgen's cholesterol drug Repatha® and, more recently, incretin therapies for obesity, Dr. Djedjos brings invaluable clinical and regulatory experience directly relevant to Moonwalk's mission.

“This financing brings us closer to developing a new generation of adipose-targeted medicines designed to improve outcomes for people living with obesity and related cardiometabolic diseases,” said Dr. Aravanis. As Moonwalk takes its next steps, the industry will be watching closely to see if its targeted approach can deliver on its promise to remodel not just adipose tissue, but the future of metabolic medicine itself.